He Blamed Gym Training Until Cancer Struck

Therapist taking notes while man sits on couch — Photo: Motortion Films / Shutterstock

The most dangerous diagnostic trap for young adults is not exotic biology but everyday plausibility: fitting worrisome symptoms into a tidy lifestyle story—until the body refuses the script.

The Short Version

A 28-year-old UK man, Marco Choi, attributed weeks of headaches, muscle aches, cold sweats, and dark stools to gym training and iron tablets; he later collapsed at work and was diagnosed with diffuse large B‑cell lymphoma (DLBCL), an aggressive blood cancer.
Iron supplements can darken stool and confuse lay interpretation, but they do not cause lymphoma; supplements also cannot cure cancer and can interfere with treatment.
Blood in the stool warrants medical evaluation; while often benign, it is an established alarm symptom across several conditions, including bowel cancer.
Young adults frequently misattribute persistent symptoms to stress, exercise, or minor illness, which contributes to pre-diagnostic delay; clinicians may also down-prioritize cancer at this age.

What happened in the Choi case, and why it resonates

According to published reporting, Choi developed headaches, muscle aches, cold sweats, and noticed blood in his stool in November 2023. Because he was training at the gym and taking iron tablets, he reasoned the darker stool and fatigue-like symptoms came from supplements and exertion. On December 13, he collapsed at work; on January 25, 2024, he received a diagnosis of diffuse large B‑cell lymphoma, an aggressive malignancy of B lymphocytes that can present with systemic “B symptoms” such as night sweats and rapid clinical decline. The sequence is sadly familiar: plausible self-explanations delay escalation until an acute event forces care. A single case never stands for a population, but it cleanly illustrates a recurrent human pattern and a solvable problem of threshold—when to stop normalizing and seek evaluation.

One detail in his story—the bathroom finding—is especially teachable. Iron tablets can indeed darken stool, sometimes dramatically, so a person primed by supplements and heavy workouts will often read color changes as expected. Yet “black” tarry stool or visible red blood is not the same as the flat gray-green darkening common with iron; persistent bleeding or a distinct change from one’s baseline should prompt medical review. That is not because blood equals cancer, but because bleeding has a differential diagnosis that ranges from hemorrhoids to ulcers to inflammatory disease to malignant lesions—across the gastrointestinal tract—and triage relies on not dismissing the alarm outright.

The biology and the misfit: stool blood and a blood cancer

Readers rightly ask how a gastrointestinal sign squares with lymphoma, a hematologic cancer. The point is not that blood in stool “means” lymphoma. It does not. DLBCL most often presents as a rapidly enlarging lymph node or a mass in lymphoid or extranodal tissue, accompanied by constitutional symptoms such as fevers, drenching night sweats, and weight loss. Gastrointestinal bleeding is more classically tied to local GI pathology or anticoagulant effects, not to B‑cell malignancy per se. In Choi’s account, the stool change appears in the narrative arc because it functioned psychologically—it made his overall experience seem compatible with a benign, supplement-related explanation—not because it was pathognomonic of his lymphoma. That distinction matters: people can carry two processes at once, or one salient sign can be a red herring. The rule to carry forward is simpler: persistent or unexplained bleeding merits evaluation, regardless of what else seems to “explain” it.

DLBCL itself is aggressive but treatable. Diagnosis hinges on tissue biopsy demonstrating large malignant B cells and immunophenotypic markers, followed by staging with imaging and, when indicated, central nervous system assessment. Standard therapy is multi-agent immunochemotherapy, often built on rituximab with anthracycline-based regimens. The disease’s tempo is fast, which is why collapsing clinical status can be the moment that breaks through patient normalization and triggers definitive workup. The case’s take-home is less about any single symptom than about the cognitive pathway that delayed attention to a cluster of systemic changes.

Why young adults normalize dangerous symptoms

Choi’s reasoning tracks with a broad evidence base on symptom appraisal in adolescents and young adults. Qualitative studies consistently find that most young adults first attribute persistent or nonspecific symptoms—fatigue, aches, weight change, bowel shifts—to stress, exercise, minor infections, or supplements; many delay seeking care, and when they do, clinicians likewise face a low prior probability of cancer in this age band and may initially favor benign diagnoses. This two-step dynamic—patient delay followed by conservative initial clinician framing—does not imply negligence; it reflects Bayesian thinking in the real world. But its cumulative effect is diagnostic lag, which matters far more in fast-tempo cancers like DLBCL than in indolent diseases.

Improving this requires better thresholds, not universal alarm. For patients: a simple rule of thumb is persistence and pattern. If a new symptom cluster lasts more than a few weeks, worsens, or adds red flags (fevers, night sweats, unintentional weight loss, bleeding, severe pain, syncope), book an evaluation rather than seeking reassurance from supplements, workouts, or the internet. For clinicians: structured “safety-netting” and timed reassessment reduce misses—if symptoms persist beyond an agreed interval or new red flags emerge, escalate testing or referral.

Supplements: what they can do—and cannot

Two separate issues often get conflated: appearance effects and disease effects. Iron can change stool color, confusing lay interpretation, but that is not evidence that iron masks cancer in a clinically meaningful way; it simply muddies the heuristic of “darker stool equals bleeding.” On the disease side, the National Cancer Institute’s guidance is blunt: dietary supplements have not been shown to cure or slow cancer, and some can interact with oncologic therapies, altering efficacy or toxicity. For anyone under evaluation for or undergoing cancer treatment, disclose all supplements—vitamins, botanicals, “pre-workout” mixes—to clinicians. The risk is not theoretical; pharmacokinetic interactions and coagulation effects are real.

For people on iron legitimately—say, for iron-deficiency anemia—the same vigilance applies. If stool color changes abruptly from your supplement baseline, if you see red blood, or if systemic symptoms accrue, you do not “already have the explanation.” You have two facts, and one may demand its own workup.

How to think about bleeding and bowel changes without catastrophizing

Panic is not a plan; pattern recognition is. Evidence-based guidance treats visible blood in stool, black tarry stools, or persistent bowel habit changes as “alarm” features that warrant medical review, especially if they persist or recur. In middle age and beyond, such findings often trigger prompt GI evaluation. In younger adults, a stepwise approach still applies: confirm the finding, consider common benign causes, but set a short leash—if bleeding persists, recurs, or couples with systemic symptoms, escalate. Across age groups, the point is not self-diagnosis but timely rule-out of serious conditions when the signal is strong enough.

For systemic symptoms that travel together—night sweats, unexplained fevers, weight loss—hematologic evaluation should be on the table. These are the classic “B symptoms” that, in combination and persistence, move the prior for lymphoid malignancy. Young adults are not exempt from that math; they merely start at a lower baseline probability, which makes thresholds and timelines central to good outcomes.

A 28-year-old came in with three days of right-sided belly pain and a CT read as an appendix abscess. The appendix was fine. The mass was an undescended testis that had twisted and died, and his empty scrotum was never written down. https://t.co/ueplYVT8yX

— Wenchang Yue (@WenchangYue) November 1, 2026

What this case teaches—without overgeneralizing

Choi’s experience is best read as a practical guide to thresholds rather than a call to pathologize every gym ache or supplement side effect. Three lessons hold up: first, persistent or escalating clusters of symptoms deserve evaluation; second, bleeding—especially if new, recurrent, or coupled with systemic signs—gets seen; third, supplements explain some appearances but solve no cancers and can complicate therapy. If you are a patient, set a timer on symptoms; if you are a clinician, agree on that timer and what happens when it rings. Cases like this will keep appearing until that simple discipline becomes habit.